Meta-analysisindependent cross-checkabstract checked★ key study I-SRC-110 in-depth review
Most side effects listed for statins are not caused by them
Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.
Overview
Cholesterol Treatment Trialists' (CTT) Collaboration. Lancet 2026 · PMID 41655587 · DOI 10.1016/S0140-6736(25)01578-8
In blinded trials with 124,000 people, only a few listed side effects (mainly liver-test changes) were more common on statins, and only slightly.
Does the study support the specific claim? No · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Check statin side effects
- How was the study done?
Meta-analysis of blinded trials
- How many people, animals or samples were studied?
123,940 participants
- What was actually found?
Only 4 of 66 listed harms confirmed; small excess
- How large was the observed effect?
Liver tests +0.13% per year
- What do the results mean in everyday life?
Statins are safer than labels suggest
- What are the study's limitations?
Rare events may be missed
- What does it say about Elawady's specific claim?
Contradicts a ban
- Do the results apply to Germany and Europe?
High
Scientific in-depth review
1. Full reference
- Authors
- Cholesterol Treatment Trialists' (CTT) Collaboration
- Journal
- Lancet
- Year
- 2026
- Identifier
- PMID 41655587 DOI 10.1016/S0140-6736(25)01578-8
- Verification
- verified – PubMed efetch 2026-10-26; Crossref works record checked
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
Funded by British Heart Foundation, UK MRC and Australian NHMRC; Oxford department policy of not accepting industry honoraria.
2. Research question
Do the adverse effects listed in statin product labels occur more often with statins than with placebo in blinded trials?
3. Study design and population
- Study design
- Meta-analysis – Individual-participant-data meta-analysis of double-blind RCTs
- Population
Participants in 19 statin-vs-placebo trials (>=1000 participants, >=2 years) and 4 intensity trials
- Country
International
- Period
Published 2026
- Sample size
123,940 participants (statin vs placebo); median follow-up 4.5 years
- Inclusion and exclusion criteria
Double-blind trials, >=1000 participants, >=2 years
4. Methods and endpoints
- Exposure / intervention
Statin
- Comparator
Placebo or less intensive statin
- Endpoints
66 undesirable outcomes listed in product labels (beyond muscle and diabetes)
- Statistical methods
Event rate ratios; false discovery rate control
5. Actual results
- Results
Only 4 of 66 label-listed outcomes were significant: abnormal liver transaminases 0.30% vs 0.22% per annum (RR 1.41, 1.26-1.57), other liver-test abnormalities 0.25% vs 0.20% (RR 1.26, 1.12-1.41; combined absolute annual excess 0.13%), urinary composition alteration RR 1.18 (1.04-1.33), oedema 1.38% vs 1.31% (RR 1.07, 1.02-1.12). No support for cognitive impairment, depression, sleep disturbance or peripheral neuropathy.
- Absolute risks
Absolute annual excess of 0.13% for combined liver-test abnormality (reported).
- Authors' conclusion
Blinded trial data do not support causal relationships between statins and most conditions listed in product labels; labels should be revised.
6. Strengths
- Double-blind IPD from very large trials
- Multiplicity control
7. Weaknesses
- Trials not designed for rare adverse events
- Authors' group conducted many included trials
8. Risk of bias
- Orienting tool
- AMSTAR 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- low
- Rationale
Blinded comparisons avoid nocebo bias.
9. Assessment of the statistical interpretation
CIs log-symmetric; absolute excesses small (0.05-0.08 points per year; stats/C-SRC-60_statins.py).
10. Relevance to the specific claim
Most side effects attributed to statins are not caused by them; real excess harms (muscle symptoms, diabetes, liver-test changes) are small. This undermines a blanket ban.
11. Independent contrary findings
I-INTB-19, I-INTB-20 (muscle, diabetes harms are real but small).
12. Transferability to Germany and Europe
Directly applicable.
13. Overall methodological judgement
High-quality evidence that statin harms are limited.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | low |
| Precision of results | high |
| Directness | direct |
| Reproducibility | replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
15. Linked fact checks
- For six or seven years he alone has said that statins (Crestor, Ator, Lipitor) are forbidden, and that Controloc (pantoprazole) is forbidden. – Studies contradicting or limiting the claim